Core Viewpoint - The stock price of HeFu China (603122) has experienced significant volatility, with a cumulative increase of 336.83% over a period of sixteen trading days, raising concerns about potential irrational market behavior and risks associated with trading [1] Summary by Relevant Sections Stock Price Movement - HeFu China's stock price has shown a cumulative increase of over 20% in three consecutive trading days (December 4, 5, and 8), which is classified as abnormal trading behavior according to the Shanghai Stock Exchange [1] - As of December 8, the stock closed at 29.18 yuan per share, marking its historical peak [1] Trading Risks - The company has indicated that the stock price has significantly deviated from its fundamental value, suggesting that investors may face considerable risks in trading [1] - The stock has hit the daily limit up price for sixteen trading days and has encountered abnormal trading conditions six times, with three instances of severe abnormal fluctuations [1] Shareholder Actions - HeFu China's controlling shareholder, HeFu (Hong Kong) Holdings Limited, has a plan to reduce its holdings, although no shares have been sold as of December 8 [1] - The company asserts that there are no undisclosed significant matters that need to be reported [1]

Core Viewpoint - The stock price of HeFu Medical Technology Co., Ltd. has experienced a significant deviation from its fundamentals, with a cumulative increase of over 20% in three consecutive trading days, indicating potential risks for investors [1] Stock Performance Summary - From October 28, 2025, to December 8, 2025, the company's stock closed at the daily limit price on sixteen trading days, with six instances of abnormal price fluctuations and three instances of severe abnormal fluctuations [1] - The cumulative increase in stock price during this period reached 336.83%, with the closing price on December 8 being 29.18 yuan per share, marking a historical peak [1] Market Sentiment and Risks - The recent continuous rise in stock price suggests an overheated market sentiment and irrational speculation, significantly exceeding the growth rates of the industry and the Shanghai Composite Index during the same period [1] - The stock price is now at a level that is markedly higher than the company's fundamentals, posing a risk of a rapid decline at any moment [1]

证券代码：603122 证券简称：合富中国 公告编号：临 2025-066 合富（中国）医疗科技股份有限公司 股票交易异常波动暨风险提示公告 本次股价连续上涨期间，公司股票流通换手率亦出现较大波动情形，击 鼓传花效应明显。敬请广大投资者注意甄别、理性判断。 公司当前股价涨幅与公司经营业绩、行业情况严重偏离，请投资者关注 公司业绩波动及估值偏高风险，勿受市场情绪过热影响，理性决策，审慎投资， 注意交易风险，避免产生较大投资损失。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 合富（中国）医疗科技股份有限公司（以下简称"公司"）股票价格于 2025 年 12 月 4 日、12 月 5 日及 12 月 8 日连续三个交易日内日收盘价格涨幅偏 离值累计超过 20%，根据上海证券交易所的有关规定，属于股票交易异常波动情 形。 公司股价累计涨幅已严重偏离基本面，投资者参与交易可能面临较大风 险。自 2025 年 10 月 28 日至 2025 年 12 月 8 日，公司股票有十六个交易日以涨 停价收盘，并 6 次触及股价 ...

合富中国（603122）(603122.SH)发布公告，公司股票价格于2025年12月4日、12月5日及12月8日连续三 个交易日内日收盘价格涨幅偏离值累计超过20%，根据上海证券交易所的有关规定，属于股票交易异常 波动情形。经公司发函核实，截至2025年12月8日，控股股东合富(香港)控股有限公司尚未减持所持公 司股份。 ...

智通财经APP讯，合富中国(603122.SH)发布公告，公司股票价格于2025年12月4日、12月5日及12月8日 连续三个交易日内日收盘价格涨幅偏离值累计超过20%，根据上海证券交易所的有关规定，属于股票交 易异常波动情形。经公司发函核实，截至2025年12月8日，控股股东合富(香港)控股有限公司尚未减持 所持公司股份。 ...

编辑：小羊 合富中国（ 603122 ）公告，合富医疗科技股份有限公司股票价格于2025年12月4日、12月5日及 12月8日连续三个交易日内日收盘价格涨幅偏离值累计超过20%。公司股价累计涨幅已严重偏离基 本面，投资者参与交易可能面临较大风险。 自2025年10月28日至2025年12月8日，公司股票有十六个交易日以涨停价收盘，并6次触及股价异 常波动、3次触及严重异常波动情形，期间累计涨幅高达336.83%。截至12月8日收盘，公司股价为 29.18元/股，处于历史最高位。股价短期内连续上涨，存在市场情绪过热、非理性炒作风险，已明 显高于同期行业及上证指数涨幅，且严重显著偏离公司基本面，随时存在快速下跌风险。 ...

人民财讯12月8日电，合富中国（603122）12月8日发布股票交易异常波动暨风险提示公告称，自2025年 10月28日至2025年12月8日，公司股票有十六个交易日以涨停价收盘，并6次触及股价异常波动、3次触 及严重异常波动情形，期间累计涨幅高达336.83%。截至12月8日收盘，公司股价为29.18元/股，处于历 史最高位。股价短期内连续上涨，存在市场情绪过热、非理性炒作风险，已明显高于同期行业及上证指 数涨幅，且严重显著偏离公司基本面，随时存在快速下跌风险。公司控股股东合富(香港)控股有限公司 存在减持计划，经公司发函核实，截至2025年12月8日，控股股东合富(香港)控股有限公司尚未减持所 持公司股份。 ...

合富中国公告称，公司股票于2025年12月4日、5日及8日连续三个交易日涨幅偏离值累计超20%，属异 常波动。10月28日至12月8日累计涨幅336.83%，16个交易日涨停，6次触及异常波动、3次触及严重异 常波动。截至12月8日，股价29.18元/股创历史新高，静态市盈率421.35倍，远高于行业的28.86倍。 2025年第三季度净利润为 -504.80万元，同比降225.26%。控股股东有减持计划，但截至12月8日尚未减 持，提醒投资者注意风险。 ...

格隆汇12月8日｜据合富中国公告，合富医疗科技股份有限公司股票价格于2025年12月4日、12月5日及 12月8日连续三个交易日内日收盘价格涨幅偏离值累计超过20%。公司股价累计涨幅已严重偏离基本 面，投资者参与交易可能面临较大风险。自2025年10月28日至2025年12月8日，公司股票有十六个交易 日以涨停价收盘，并6次触及股价异常波动、3次触及严重异常波动情形，期间累计涨幅高达336.83%。 截至12月8日收盘，公司股价为29.18元/股，处于历史最高位。股价短期内连续上涨，存在市场情绪过 热、非理性炒作风险，已明显高于同期行业及上证指数涨幅，且严重显著偏离公司基本面，随时存在快 速下跌风险。 ...

Group 1 - The controlling shareholder of HeFu China, HeFu (Hong Kong) Holdings Limited, plans to reduce its stake by up to 7.9611 million shares, representing 2% of the total share capital, within three months [1][3] - As of the end of Q3, HeFu Hong Kong held 55.00% of HeFu China, and after the reduction, its stake may decrease to 53.00%, but it will still maintain absolute control over the company [1][3] - The purpose of the share reduction is to enhance operational funds, including financing for projects like the MRI navigation radiation therapy system [1][3] Group 2 - HeFu China operates in the pharmaceutical distribution industry, which has faced significant challenges due to policies like drug separation and volume-based procurement, squeezing profit margins for traditional pharmaceutical distributors [2][4] - Despite efforts to diversify through platforms for centralized business operations, medical product distribution, and hospital empowerment, HeFu China has experienced a continuous decline in performance [2][4] - For the first three quarters of 2025, the company reported revenue of 549 million yuan, a year-on-year decrease of 22.80%, and a net loss attributable to shareholders of 12.3862 million yuan, a year-on-year increase in losses of 146.65% [2][4]